Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 4-12

  Engelhardt, G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Anti inflammatory; Cyclooxygenase; Meloxicam; Pharmacology; Prostaglandins

Indexed keywords

LEUKOTRIENE B4; LEUKOTRIENE C4; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

ADJUVANT DISEASE; ANIMAL CELL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; FEVER; GASTROINTESTINAL TRACT; GUINEA PIG; HUMAN; HUMAN CELL; KIDNEY; LEUKOCYTE MIGRATION; NONHUMAN; PAIN; PAW EDEMA; PERITONEUM EXUDATE; PERITONEUM MACROPHAGE; PLEURA FLUID; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; ULCEROGENESIS;

EID: 0029867761     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.4     Document Type: Article

References (69)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature New Biol 1971;231:232-5.
2. Vane JR. In: Robinson HJ, Vane JR, eds. Prostaglandin synthetase inhibitors. New York: Raven Press, 1974.
3. Langman FJS, Weil J, Wainwright P et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drags. Lancet 1994;343:1075-8.
4. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
5. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9.
6. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89:3917-21.
7. Wong WYL, Richards JS. Evidence for two antigenically district molecular weight variants of prostaglandin H synthase in the rat ovary. Mol Endocrinol 1991;5:1269-79.
8. Xie W, Chipman JG, Robertson DL, Erikson RC, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by RNA splicing. Proc Natl Acad Sci USA 1991;88:2692-8.
9. Loll PJ, Garavito RM. The isoforms of cyclooxygenase: structure and function. Exp Opin Invest Drugs 1994;3:1171-80.
10. Vane JR. Towards a better aspirin. Nature 1994;367:215-6.
11. Lee SH, Soyoola E, Chanmugam P et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-8.
12. O'Sullivan MG, Chilton FH, Huggins EM, McCall CE. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthetase. J Biol Chem 1992;267:14547-50.
13. Akarasereenont P, Mitchell JA, Bakhle YS, Thiemermann C, Vane JR. Comparison of the induction of cyclooxygenase and, nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur J Pharmacol 1995;273:121-8.
14. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P. In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther 1994;270:1340-4.
15. Vane JR, Mitchell JA, Appleton J et al. Inducible isoforms of cyclooxygenase and nitric synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-50.
16. Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 1993;268:23448-54.
17. Szcepanski A, Moatter T, Carley WW, Gerritsen ME. Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1. Arthritis Rheum 1994;37:495-503.
18. Sano H, Hla T, Maier JAM et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
19. Knott I, Dieu M, Burton M, Houbion A, Remacle J, Raes M. Induction of cyclooxygenase by interleukin-1: comparative study between human synovial cells and chondrocytes. J Rheumatol 1994;21:462-6.
20. 2 and cyclooxygenase-2. Eur J Biochem 1994;226:125-31.
21. Crofford LJ, Wilder RL, Ristimaki AP et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissue. Effects of interleukin-1β, phorbol ester and corticoids. J Clin Invest 1994;93:1095-101.
22. Meade EA, Smith WL, DeWitt DC. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
23. Mitchell JA, Akarasereemont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7.
24. Engelhardt G. Meloxicam inhibits preferentially COX-2. Eur J Clin Pharmacol 1994;47:A98.
25. Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem Pharmacol 1996;51:21-8.
26. Churchill L, Graham A, Farina P, Grob P. Inhibition of human cyclooxygenase-2 (COX-2) by meloxicam. XIIIth European Congress of Rheumatology, Amsterdam, June 18-23,1995.
27. Pairet M, Engelhardt G. The preferential inhibition of COX-2 by meloxicam is highly dependent on the structure of the drug. Rheumatol Eur 1995;24(suppl. 3):272.
28. Murray MD, Brater DC. Renal toxicity of non-steroidal anti-inflammatory drugs. Annu Rev Pharmacol Tox 1993;32:435-65.
29. Rosenkranz B, Fischer C, Meese CO, Frölich JC. Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man. Br J Clin Pharmacol 1986;31:309-17.
30. Whittle BJR, Higgs GA, Eakins KB, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271-3.
31. Harada Y, Hatawaka K, Kawamura M et al. Possible involvement of inducible cyclooxygenase (COX) in carrageenan-induced pleurisy. World Congress of Inflammation 1993, Vienna, October 10-15, 1993;abstract no. P153.
32. Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996;51:29-38.
33. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
34. Engelhardt G, Homma D, Schnitzler C. Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995;44:548-55.
35. Chen JYP, Beckman H. A satisfactory apparatus for study of analgesia in mice. Science 1951;113:631.
36. Haffner F. Experimentelle Prüfung schmerzstillender Mittel. Dtsch Med Wochenschr 1929;54:731-3.
37. Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with capsaicin and morphine. Naunyn-Schmiedeberg's Arch Pharmakol 1982;312:116-22.
38. Randall LO, Selitto JJ. A method for measurement of analgesic activity or inflammation tissue. Arch Int Pharmacodyn 1957;111:409-19.
39. Justus C, Quirke JF. Dose response relationship for the antipyretic effect of meloxicam in an endotoxin model in cats. Veterin Res Commun 1995;19:321-30.
40. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
41. Kaufman DW, Kelly JP, Sheeman JE et al. Non-steroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-94.
42. Engelhardt G, Bögel R, Krug I, Walcher I. Meloxicam: lack of correlation between inhibition of PG-biosynthesis in the inflammatory field and in the stomach. Magy Rheumatol 1991;32(suppl.):354.
43. Busch U. The pharmacokinetics of meloxicam in animals. Scand J Rheumatol 1994;Suppl 98:A119.
44. Engelhardt G, Homma D, Schlegel K, Schnitzler C, Utzmann R. General pharmacology of meloxicam. Part 1. Gen Pharmacol 1996;51:29-38.
45. Ghosh P, Brooks P. Chondroprotection - exploring the concept. J Rheumatol 1991;18:161-6.
46. Mohr W, Lehmann H. Chondroneutrality of meloxicam in spontaneously occuring osteoarthrosis in rats and mice. Congress of Degenerative and Inflammatory Processes in the Joints, Bari, Italy, September 29-October 1,1994.
47. Rainsford K, Ying C, Smith F. Comparative effects of meloxicam on cartilage-synovial components of joint injury in vitro. 2nd International Congress of the Osteoarthritis Research Society, Orlando, Florida, December 9-11, 1994.
48. Bassleer C, Franchimont P. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. XIIIth European Congress of Rheumatology, Amsterdam, June 18-23, 1995:abstract no. E46.
49. Swingle KF. Evaluation of anti-inflammatory activity. In: Scherer RA, Whitehouse MW, eds. Anti-inflammatory agents. New York: Academic Press, 1974.
50. Tausch G, Eberl R. Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflamm 1978;1:365-8.
51. Murphy JE. Piroxicam in the treatment of acute gout. J Intern Med Res 1979;7:507-10.
52. Collier HOJ, Hogate JA, Schachter M, Shorley PG. An apparent bronchoconstrictor action of bradykinin and its suppression by some anti-inflammatory drugs. J Physiol 1959;149:54P-5P.
53. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin peroxides. Proc Natl Acad Sci USA 1975;72:2994-8.
54. 2 by PAF-acether from guinea- pig lungs involves mechanisms distinct from those for leukotriene. Br J Pharmacol 1984;82:565-75.
55. Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Non-immunological production of leukotrienes induced by platelet-activating factor. Science 1982;218:286-8.
56. Engelhardt G, Homma D, Schlegel K, Schnitzler Chr, Utzmann R. General pharmacology of meloxicam. Part. 2. Gen Pharmacol 1995;in press.
57. Türck D, Busch U, Heinzel G, Greischel A, Nehmiz G, Narjes H. The basic clinical pharmacokinetics of meloxicam, a new NSAID. Scand J Rheumatol 1994;Suppl 98:A120.
58. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Meloxicam: pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995;23:1206-13.
59. Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exp Clin Res 1990;16:53-6.
60. 14C]meloxicam in joints of rats with adjuvant arthritis. Drugs Exp Clin Res 1990;17:49-52.
61. Busch U, Schmid J. Pharmacokinetic properties of meloxicam: a new NSAID in different species. Clin Exp Rheumatol 1987;5(suppl. 2):145.
62. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35(suppl. 1): 68-77.
63. Copeland RA, Williams JM, Giannaras J et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994;91:11202-6.
64. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
65. Gierse JK, Hauser SD, Creely DP et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 1995;305:479-84.
66. Chan CC, Gordon R, Brideau C et al. In vivo pharmacology of L-745,337: a novel non-steroidal anti-inflammatory agent (NSAID) with an ulcerogenic sparing effect in rat and monkey stomach. Can J Physiol Pharmacol 1994;72(suppl. 1):266.
67. Bjamason I, Hayllar J, Parker J, Schupp J, MacPherson A. A randomised, double blind, crossover comparative endoscopy study on the gastroduodenal tolerability of flusolide and naproxen. Gastroenterology 1994;106(supl. 4):A53.
68. Bennett A, Tavares IA. NSAIDs, COX-2 inhibitors, and the gut. Lancet 1995;346:1105.
69. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzheimittel Forsch 1995;45:1093-5.